Gotowa bibliografia na temat „Neutralizing antibodies”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Neutralizing antibodies”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Neutralizing antibodies"
Vinson, Valda. "Protective neutralizing antibodies". Science 369, nr 6506 (20.08.2020): 930.13–932. http://dx.doi.org/10.1126/science.369.6506.930-m.
Pełny tekst źródłaDempsey, Laurie A. "Zika-neutralizing antibodies". Nature Immunology 18, nr 6 (czerwiec 2017): 603. http://dx.doi.org/10.1038/ni.3762.
Pełny tekst źródłaBell, Elaine. "Neutralizing antibodies revisited". Nature Reviews Immunology 2, nr 6 (czerwiec 2002): 387. http://dx.doi.org/10.1038/nri833.
Pełny tekst źródłaMuharemagic, D., A. S. Zamay, S. M. Ghobadloo, J. C. Bell i M. V. Berezovski. "APTAMER-FACILITATED PROTECTION OF ONCOLYTIC VIRUS FROM NEUTRALIZING ANTIBODIES". Siberian Medical Review, nr 5 (2016): 116. http://dx.doi.org/10.20333/25000136-2016-5-116-2.
Pełny tekst źródłaKadkhoda, Kamran. "COVID ‐19: are neutralizing antibodies neutralizing enough?" Transfusion 60, nr 7 (3.06.2020): 1602–3. http://dx.doi.org/10.1111/trf.15897.
Pełny tekst źródłaBjorkman, Pamela. "Neutralizing antibodies against coronaviruses". Microscopy and Microanalysis 27, S1 (30.07.2021): 1112–13. http://dx.doi.org/10.1017/s1431927621004177.
Pełny tekst źródłaNoronha, A. "Neutralizing antibodies to interferon". Neurology 68, Issue 24, Supplement 4 (11.06.2007): S16—S22. http://dx.doi.org/10.1212/01.wnl.0000277705.63813.84.
Pełny tekst źródłaCorti, Davide, i Antonio Lanzavecchia. "Broadly Neutralizing Antiviral Antibodies". Annual Review of Immunology 31, nr 1 (21.03.2013): 705–42. http://dx.doi.org/10.1146/annurev-immunol-032712-095916.
Pełny tekst źródłaGrauer, A., H. Reinel, R. Ziegler i F. Raue. "Neutralizing Antibodies Against Calcitonin". Hormone and Metabolic Research 25, nr 09 (wrzesień 1993): 486–88. http://dx.doi.org/10.1055/s-2007-1002156.
Pełny tekst źródłaO'Connell, Nicola, i Bronwen Roper. "Testing for neutralizing antibodies". British Journal of Neuroscience Nursing 3, nr 2 (luty 2007): 65–67. http://dx.doi.org/10.12968/bjnn.2007.3.2.23140.
Pełny tekst źródłaRozprawy doktorskie na temat "Neutralizing antibodies"
Ovcina, Emira. "An immune response to peptides selected with neutralizing antibodies". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0019/MQ59191.pdf.
Pełny tekst źródłaBonsall, David George. "The role of neutralizing antibodies in HIV-1 infection". Thesis, Imperial College London, 2011. http://hdl.handle.net/10044/1/6360.
Pełny tekst źródłaZhang, Jianchao. "HIV-1/SIV neutralizing antibody gene delivery a novel vaccination approach /". Columbus, Ohio : Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1237924213.
Pełny tekst źródłaLam, Sin Man. "Neutralizing antibodies and the biological response to interferon-beta therapy". Thesis, University of British Columbia, 2010. http://hdl.handle.net/2429/26977.
Pełny tekst źródłaBurke, Karen L. "Antigen chimaeras of poliovirus". Thesis, University of Reading, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.328967.
Pełny tekst źródłaWiley, James A. "Monoclonal anti-idiotypes induce neutralizing antibodies to enterovirus-70 conformational epitopes". Thesis, University of Ottawa (Canada), 1992. http://hdl.handle.net/10393/7649.
Pełny tekst źródłaDerby, Nina Rafterman. "Designing immunogens to elicit broadly reactive neutralizing antibodies to the HIV envelope /". Thesis, Connect to this title online; UW restricted, 2007. http://hdl.handle.net/1773/9302.
Pełny tekst źródłaAlpert, Michael. "Antibodies in Vaccine Protection against SIV and HIV-1 Infection". Thesis, Harvard University, 2011. http://dissertations.umi.com/gsas.harvard:10057.
Pełny tekst źródłaYari, Fayezeh. "Expression of recombinant neutralizing anti-HIV-1 antibodies in bacteria and eukaryotic cells /". Stockholm : Karolisnska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-079-4/.
Pełny tekst źródłaMolinos, Albert Luis Manuel. "Targeting a major HIV-1 vulnerability region: the gp41 membrane proximal external region. Balance between neutralizing and non-neutralizing antibodies and implications for vaccine design". Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/392728.
Pełny tekst źródłaLa generación de anticuerpos ampliamente neutralizantes contra el VIH-1 es el principal objetivo de una vacuna que sea capaz de controlar la epidemia causada por el virus. La glicoproteína de la envuelta del VIH-1 es el único antígeno viral expuesto en la membrana del virus y la principal diana de respuestas humorales protectoras. Dentro de esta proteína se han identificado regiones funcionales que son reconocidas por anticuerpos ampliamente neutralizantes, lo cual ha permitido establecer puntos de vulnerabilidad del virus hacia los que una vacuna debería dirigirse. En este contexto, la región externa próxima a la membrana (MPER) de gp41 es uno de los sitios de vulnerabilidad del virus más representativos, ya que está altamente conservado, juega un papel crucial en la infectividad del virus y es reconocido por anticuerpos protectores ampliamente neutralizantes. Sin embargo, su localización, contigua a la membrana, hace del MPER un dominio poco accesible, expuesto de forma transitoria, hidrofóbico y altamente influenciado por lípidos de membrana. En consecuencia, su inmunogenicidad presenta una alta complejidad que debe ser explorada en mayor profundidad. En esta tesis, aportamos nuevo conocimiento sobre la inmunogenicidad del MPER a nivel de la infección natural y en modelos animales de inmunización. Hemos evaluado miniproteínas basadas en gp41 que sobreexponen el MPER, para ser utilizadas como 1) nuevas plataformas para la detección de anticuerpos anti-MPER y 2) prototipos de inmunógenos presentados en proteoliposomas de diversa composición. Los resultados han revelado una alta inmunogenicidad del MPER en humanos, que correlaciona con la respuesta global contra la proteína de la envuelta. Esto sugiere que el sistema inmune no tiene una especial restricción para la generación de este tipo de anticuerpos. Sin embargo, los anticuerpos detectados mostraron una funcionalidad heterogénea, en términos de capacidad neutralizante y competición por diferentes epítopos, independientemente de la especificidad por el MPER. Además, los resultados fueron reproducidos en animales inmunizados. En estos últimos, conseguimos generar un alto título de anticuerpos específicos, potenciados por la incorporación en los proteoliposomas de mezclas lipídicas complejas que mimetizaban las de la partícula viral. Sorprendentemente, se generó una respuesta inmunodominante no neutralizante que solapaba con un epítopo reconocido por el anticuerpo neutralizante 2F5. En resumen, la repuesta humoral natural contra el MPER en pacientes infectados por el VIH-1 y la generada en modelos animales mediante inmunización comparten ciertas características como son la especificidad y la escasa capacidad neutralizante. Estos resultados sugieren que el balance entre la respuesta neutralizante y no neutralizante podría tener una importante relevancia en la respuesta global contra el MPER. De este modo, es necesario un mayor refinamiento de inmunógenos que sean capaces de sortear respuestas no neutralizantes. Este rediseño se verá altamente beneficiado del conocimiento generado a partir de nuevos anticuerpos monoclonales contra el MPER que reflejen la heterogeneidad funcional observada en nuestros estudios.
The elicitation of broadly neutralizing antibodies (bNAbs) against HIV-1 constitutes the major goal of an effective vaccine able to control the epidemic caused by this virus. The HIV-1 envelope glycoprotein is the only viral antigen exposed on the surface of the virus and the main target of protective humoral responses. The identification within this protein of functional regions recognized by bNAbs has delineated an HIV-1 vulnerability map that has guided efforts for rational immunogen design. In this regard, the gp41 Membrane Proximal External Region (MPER) is a major HIV-1 vulnerability site because is highly conserved, plays a major role in viral infectivity and is targeted by protective bNAbs. However, its localization, next to the viral membrane, results in a hardly accessible, transiently exposed and hydrophobic domain, strongly influenced by membrane lipids. Therefore, the immunogenicity of the MPER offers a high level of complexity that needs to be further explored. In this thesis we provide new knowledge on the MPER immunogenicity in both natural HIV-1 infection and immunization in animal models. We generated gp41-based miniproteins which properly exposed the MPER region that have been used 1) as novel platforms for MPER antibody detection and 2) as immunogen candidates presented in different proteoliposome compositions. In humans, the results revealed a strong immunogenicity of the MPER that correlated with a global response against the envelope glycoprotein suggesting no special constraints for the immune system to target this region. However, the antibodies elicited showed heterogeneous functionality in terms of neutralizing capacity and epitope competition, regardless MPER specificity. Interestingly, these results were reproduced by immunization in animal models. High antibody titers were achieved that were specially enhanced by the addition of lipid mixtures mimicking the viral membrane. Interestingly, a non-neutralizing immunodominant response against an epitope that overlapped the 2F5 neutralizing antibody binding motif was identified. Overall, the anti-MPER response in both humans and animal model settings was not correlated with the neutralizing capacity and antibodies detected or induced by immunization were preferentially non-neutralizing. Our results suggest that the balance between neutralizing and non neutralizing responses may represent an important issue in the global response against MPER. Therefore, further redesign of immunogens able to skip non-neutralizing determinants will benefit from the knowledge derived from new anti-MPER antibodies that reflect the functional heterogeneous profile observed in our studies.
Książki na temat "Neutralizing antibodies"
Tovey, Michael G. Detection and quantification of antibodies to biopharmaceuticals: Practical and applied considerations. Hoboken, N.J: Wiley, 2011.
Znajdź pełny tekst źródłaO'Rourke, Katherine. Neutralizing and cross neutralizing antibodies in horses with equine infectious anemia virus. 1987.
Znajdź pełny tekst źródłaTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals. Wiley & Sons, Incorporated, John, 2011.
Znajdź pełny tekst źródłaChiodi, Francesca, i Gabriella Scarlatti, red. HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies. Frontiers Media SA, 2018. http://dx.doi.org/10.3389/978-2-88945-461-7.
Pełny tekst źródłaSchommers, Philipp, Harry Gristick, Marit J. Van Gils i Kshitij Wagh, red. Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-305-6.
Pełny tekst źródłaTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Limited, John, 2011.
Znajdź pełny tekst źródłaTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Incorporated, John, 2011.
Znajdź pełny tekst źródłaTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Incorporated, John, 2011.
Znajdź pełny tekst źródłaTovey, Michael G. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Wiley & Sons, Incorporated, John, 2011.
Znajdź pełny tekst źródłaCox, Josephine H., Stuart Z. Shapiro, Liza Dawson, Cynthia Geppert, Andrew M. Siegel i M. Patricia D’Souza. Vaccines for The Prevention and Treatment of HIV Infection. Redaktorzy Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding i Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0032.
Pełny tekst źródłaCzęści książek na temat "Neutralizing antibodies"
Robert-Guroff, Marjorie. "Neutralizing Antibodies". W Techniques in HIV Research, 179–85. London: Palgrave Macmillan UK, 1990. http://dx.doi.org/10.1007/978-1-349-11888-5_9.
Pełny tekst źródłaKunert, Renate. "The Neutralizing Anti-HIV Antibody 2G12". W Anticarbohydrate Antibodies, 147–60. Vienna: Springer Vienna, 2011. http://dx.doi.org/10.1007/978-3-7091-0870-3_6.
Pełny tekst źródłaSuitters, Amanda, i Roly Foulkes. "Cytokine-neutralizing therapeutic antibodies". W Novel Cytokine Inhibitors, 123–43. Basel: Birkhäuser Basel, 2000. http://dx.doi.org/10.1007/978-3-0348-8450-1_6.
Pełny tekst źródłaMoulard, Maxime, Mei-Yun Zhang i Dimiter S. Dimitrov. "Novel Hiv Neutralizing Antibodies Selected from Phage Display Libraries". W Antibodies, 105–17. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-1-4419-8877-5_5.
Pełny tekst źródłaAbraham, Edward. "Neutralizing antibodies and receptor constructs". W Cytokines in Severe Sepsis and Septic Shock, 285–93. Basel: Birkhäuser Basel, 1999. http://dx.doi.org/10.1007/978-3-0348-8755-7_16.
Pełny tekst źródłaLansky, David, i Carrie Wager. "Dilutional Linearity for Neutralizing Antibody Assays". W Detection and Quantification of Antibodies to Biopharmaceuticals, 309–17. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118075685.ch17.
Pełny tekst źródłaRuprecht, Ruth M. "Passive Immunization with Human Neutralizing Monoclonal Antibodies Against HIV-1 in Macaque Models: Experimental Approaches". W Therapeutic Antibodies, 559–66. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_31.
Pełny tekst źródłaZhang, Mei-Yun, i Dimiter S. Dimitrov. "Competitive Antigen Panning for Selection of HIV-1 Neutralizing Human Monoclonal Antibodies Specific for gp41". W Therapeutic Antibodies, 175–86. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_9.
Pełny tekst źródłaGrossberg, Sidney E., i Yoshimi Kawade. "The Expression of Potency of Neutralizing Antibodies for Interferons and other Cytokines". W Antibodies in Cytokines, 93–98. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5664-6_10.
Pełny tekst źródłaWu, Xueling. "HIV Broadly Neutralizing Antibodies: VRC01 and Beyond". W HIV Vaccines and Cure, 53–72. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2_3.
Pełny tekst źródłaStreszczenia konferencji na temat "Neutralizing antibodies"
Morton, Scott P., i Joshua L. Phillips. "pH Dependent Binding Energies of Broadly Neutralizing Antibodies". W 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2021. http://dx.doi.org/10.1109/bibm52615.2021.9669511.
Pełny tekst źródłaJohnsson, H., A. Silveira, L. Adamson, S. Schulman i B. Hessel. "INDUCED ANTIBODIES TO VON WILLEBRAND FACTOR (VWF)". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644112.
Pełny tekst źródłaSolodkov, P. P., T. N. Belovezhets, A. N. Chikaev, K. O. Baranov, S. V. Kulemzin, A. A. Gorchakov, S. V. Guselnikov i in. "SINGLE DOMAIN LLAMA ANTIBODIES BROADLY NEUTRALIZING SARS-COV-2 VARIANTS". W X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-127.
Pełny tekst źródłaSun, Jing, Guang Lan Zhang, Lars Rønn Olsen, Ellis L. Reinherz i Vladimir Brusic. "Landscape of neutralizing assessment of monoclonal antibodies against dengue virus". W BCB'13: ACM-BCB2013. New York, NY, USA: ACM, 2013. http://dx.doi.org/10.1145/2506583.2512359.
Pełny tekst źródłaDias, Brenda, Andrea Silva, Ariane Souza, Luma Moura, Nathália Alves, Vanessa Rocha, Ana Argondizzo, Sheila Lima, Helena Toma i Adriana Azevedo. "Neutralizing antibodies and igg avidity against SARS-CoV-2 variants". W International Symposium on Immunobiologicals. Instituto de Tecnologia em Imunobiológicos, 2023. http://dx.doi.org/10.35259/isi.2023_58035.
Pełny tekst źródłaKent, Michael, Maxwell Stefan, Brooke Harmon, Daniel Gelperin, Valerie Duva, Alyssa Wynne i Valeria Busygina. "Rapidly Adapting Neutralizing Antibodies to Related Virus Types and Subtypes." W Proposed for presentation at the Biophysical Society Annual Meeting 2021 held February 22-26, 2021. US DOE, 2021. http://dx.doi.org/10.2172/1842569.
Pełny tekst źródłaGavrilova, N. V., V. V. Vysochinskaya, E. A. Elpaeva, O. A. Dobrovolskaya, M. A. Plotnikova, A. A. Lozhkov, E. L. Zimmerman, A. A. Shaldzhyan i Y. A. Zabrodskaya. "ANTIVIRAL ACTIVITY OF MRNAS ENCODING ANTIBODIES, TARGETING INFLUENZA A HEMAGGLUTININ AND INFLUENZA B NUCLEOPROTEIN IN VITRO". W OpenBio-2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-239.
Pełny tekst źródłaRak, A. Ya, Ya A. Zabrodskaya, N. P. Gorbunov, D. S. Polyakov, D. A. Mezhenskaya, L. G. Rudenko i I. N. Isakova-Sivak. "DEVELOPMENT OF A UNIVERSAL DIAGNOSTIC TEST SYSTEM FOR DETERMINING THE TITER OF ANTIBODIES AGAINST SARS-COV-2 BY MICRONEUTRALIZATION". W X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-226.
Pełny tekst źródłaAllaf, L. Al, A. Chechushkov, T. Ushakova, V. Morozova i N. Tikunova. "INFLUENCE OF HUMORAL IMMUNE RESPONSE TO BACTERIOPHAGE ON PHAGE-THERAPY AND ANTI-BACTERIAL IMMUNITY". W X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-223.
Pełny tekst źródłaZimonina, A. A., E. Yu Prudnikova i A. R. Imatdinov. "RECOMBINANT MONOCLONAL ANTIBODIES WITH VIRUS NEUTRALIZING ACTIVITY AGAINST SARS-COV-2 DELTA AND OMICRON VARIANTS". W X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-81.
Pełny tekst źródłaRaporty organizacyjne na temat "Neutralizing antibodies"
Glassy, Mark C. Neutralizing Monoclonal Antibodies against Biological Toxins. Phase 1. Fort Belvoir, VA: Defense Technical Information Center, sierpień 1993. http://dx.doi.org/10.21236/adb176298.
Pełny tekst źródłaIvanova, Sonya, Raliza Skrobanska, Vera Kolyovska i Ivan Milanov. Do Binding Antibodies Predict Neutralizing Antibody Development in Multiple Sclerosis Patients? "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, sierpień 2018. http://dx.doi.org/10.7546/crabs.2018.08.17.
Pełny tekst źródłaIvanova, Sonya, Raliza Skrobanska, Vera Kolyovska, Ivan Milanov, Valentina Dimitrova i Veneta Bojinova. Neutralizing Antibodies against Interferon‑beta in Bulgarian Adolescent Multiple Sclerosis Patients. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, wrzesień 2018. http://dx.doi.org/10.7546/crabs.2018.09.15.
Pełny tekst źródłaMogler, Mark, i D. L. Hank Harris. Passive Immunization of Piglets Using Equine Plasma Containing PRRS Virus-Neutralizing Antibodies. Ames (Iowa): Iowa State University, styczeń 2008. http://dx.doi.org/10.31274/ans_air-180814-171.
Pełny tekst źródłaKaniewski, Laura, Jason Hocker, Mark Mogler, Matthew M. Erdman, Eric Nelson i D. L. Hank Harris. Passive Immunization of Piglets with Hyperimmune Plasma Containing Virus Neutralizing Antibodies to Porcine Reproductive and Respiratory Syndrome Virus. Ames (Iowa): Iowa State University, styczeń 2009. http://dx.doi.org/10.31274/ans_air-180814-65.
Pełny tekst źródłaMackey, Katherine, Irina Arkhipova-Jenkins, Charlotte Armstrong, Emily Gean, Johanna Anderson, Robin A. Paynter i Mark Helfand. Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Rapid Living Review. Agency for Healthcare Research and Quality (AHRQ), marzec 2021. http://dx.doi.org/10.23970/ahrqepccovidimmunity.
Pełny tekst źródłaJuni, Peter, Ashleigh R. Tuite, Issac I. Bogoch, Adalsteinn D. Brown, Yoojin Choi, Bruno R. da Costa, Gerald A. Evans i in. Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario. Ontario COVID-19 Science Advisory Table, styczeń 2021. http://dx.doi.org/10.47326/ocsat.2021.02.06.1.0.
Pełny tekst źródła